Blueprint Medicines Reports Second Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Blueprint Medicines Reports Second Quarter 2019 Financial Results

Blueprint Medicines (BPMC) Misses Q2 EPS by 13c, Revenues Beat

August 1, 2019 7:23 AM EDT

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.04), $0.13 worse than the analyst estimate of ($1.91). Revenue for the quarter came in at $5.11 million versus the consensus estimate of $1.98 million.

Second Quarter 2019 Financial Results:

Cash Position: As of June 30, 2019, cash, cash equivalents and investments were $667.3 million, as compared to $494.0 million as of December 31, 2018. This increase reflects net proceeds of approximately $327.4 million from the company's follow-on underwritten public offering of common stock, which closed in April 2019, partially offset by cash used in operations.Collaboration Revenues: Collaboration revenues were $5.1 million for the second quarter... More